5-Year Follow-up Data on CPX-351 for AML

A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.

Harry Erba, MD, PhD: We’ve been talking a little about CPX-351 [cytarabine, daunorubicin] and Jeffrey Lancet presented data at ASH [American Society of Hematology Annual Meeting], which I believe have been updated in a publication, looking at the 5-year follow-up of the CPX-351 [cytarabine, daunorubicin] vs 7+3 trial for patients with therapy-related and secondary AML [acute myeloid leukemia], or what we now call AML with myelodysplasia-related changes. The median survival stayed about the same, at just under 6 months with 7+3 and about 9½ months with CPX-351 [cytarabine, daunorubicin], with a hazard ratio of 0.7. Still, it was statistically significant at 3 and 5 years; there seems to be a plateau in the Kaplan-Meier curve. Unfortunately, they’re both plateauing at a very low number, but twice as many patients are still alive at 3 and 5 years with CPX-351 [cytarabine, daunorubicin], at around 20%, vs just under 10% with 7+3. The benefit was seen in those who were 70 to 75 years old. The real benefit, when I look at these data, seems to be for patients who go on to stem cell transplant in that remission. You’ve presented data from this V-FAST study that we’re both investigators on. Vinod, tell us about that 1.

Vinod Pullarkat, MD: The question is how to improve further upon CPX-351 [cytarabine, daunorubicin]. It comes back to the concept that we’re talking about: if adding another targeted agent to the backbone is successful. In the V-FAST trial, you have 3 arms. You have a FLT3 arm, where midostaurin is added to CPX-351 [cytarabine, daunorubicin]; you have an IDH2 arm, where enasidenib is added to CPX-351 [cytarabine, daunorubicin]; and for all the other patients who lack either FLT3 or IDH2 mutations, you had a combination of CPX-351 [cytarabine, daunorubicin] plus venetoclax. The probability looks like all these combinations are well tolerated, and in the arm that is where we have the efficacy data—which is the combination of venetoclax with CPX-351 [cytarabine, daunorubicin]—we have good CR [complete remission] rates, consulting that population, which is all adverse-risk patients. We have about a 50% CR rate, and the other arms are still in the expansion phase, but the probability looks good. One concern was whether this would produce very prolonged cytopenia, and that doesn’t seem to be the case. The data are not mature enough to know this is better than the CPX-351 [cytarabine, daunorubicin], but they looks promising.

Harry Erba, MD, PhD: In the relapsed/refractory setting, [The University of Texas] MD Anderson [Cancer Center] has looked at the combination. Courtney?

Courtney DiNardo, MD: Looping back to the initial comments, the 3- and 5-year follow-up data of CPX-351 [cytarabine, daunorubicin] were quite impressive. Everyone looked at those data and thought, “Wow. We’re seeing—especially in the patients who went to transplant, as you mentioned—a doubling of overall survival.” It was about 50% in the 5-year overall survival post-transplant. One of the main questions—going back to the conversation that has been permeating this whole discussion—is MRD [minimal residual disease], right? We assume that patients are going into a deeper remission prior to going to transplant and we’re seeing that, although that’s not something that was collected on that study, so we’re never going to know that for sure. Patients have prolonged cytopenias and often need more transfusions than you would see with 7+3, but these patients are doing quite well. If that patient is getting an intensive chemotherapy, CPX-351 [cytarabine, daunorubicin] is impressive in the long-term follow-up.

Mark Levis, MD, PhD: One other interesting point about those transplant data. We assume it’s MRD. That is the logical conclusion, and that’s what we would all put our money on. But if you look at the patient who has had induction with CPX-351 [cytarabine, daunorubicin], they don’t look like a patient with cancer. The drug gets to the marrow more than the rest of the tissue, and the damage done to that tissue, when you take a patient to allotransplant, does matter. For those patients, the GVHD [graft-vs-host disease] hits them harder, so you really wonder, is there a component of the benefit that as well?

Harry Erba, MD, PhD: Those are all great points. It’s not just adults playing with this drug. In March, the FDA approved the CPX-351 [cytarabine, daunorubicin] for pediatric patients as well, so they’ll be struggling with all these same questions. Yes, the mechanism of the benefit prior to transplant is MRD vs less toxicity. I’m not sure from the design of the study, but based on those landmark analyses, even patients over age 7—did much better if they received CPX-351 [cytarabine, daunorubicin] and went to transplant vs 7+3.

Transcript Edited for Clarity

Related Videos
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Hua-Jay “Jeff” Cherng, MD, assistant professor, medicine, Lymphoma Program, Division of Hematology and Oncology, Columbia University Irving Medical Center
Naval G. Daver, MD
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School
Harry P. Erba, MD, PhD